Clinical trials: Schizophrenia
Cognitive Impairment, Schizophrenia
Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia
The purpose of this study is to assess the safety and effects on electrical activity in the brain of an investigational drug (RL-007) for improving cognition in patients with schizophrenia
- Trial name
- NCT04822883
- Testing
- RL-007
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Recognify Life Sciences
Schizophrenia
The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia
To evaluate the safety and efficacy of Lurasidone initiated with 40mg and 80mg in treatment with acute phase patients with schizophrenia
- Trial name
- NCT05011669
- Testing
- Lurasidone
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Psychotic Disorders
Improving Cognitive Function of Aripiprazole in Treating Adolescents and Young Adults With Psychotic Disorder
This is a 24-week, observational, prospective study to evaluate the effectiveness of improving cognitive function of aripiprazole in treating adolescents and young adults with psychotic disorder in Taiwan.
- Trial name
- NCT00541502
- Sponsor
- Genovate Biotechnology Co., Ltd.,
Bipolar Disorder, Schizophrenia
Post-Authorization Safety Surveillance Study of Asenapine in Participants With Bipolar Disorder (P08307)
This study will assess asenapine (Sycrest®) use in participants with bipolar disorder; comparison will be made to the use of risperidone (RISPERDAL®CONSTA®) and olanzapine (Zyprexa®).
- Trial name
- NCT01495741
- Volunteers
- 42 people
- Sponsor
- Organon and Co
Schizophrenia
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
This study is intended to determine whether the addition of trospium chloride to xanomeline tartrate will ameliorate the peripheral cholinergic side effects that have been previously experienced with xanomeline tartrate when…
- Trial name
- NCT02831231
- Testing
- xanomeline tartrate, Trospium chloride
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Schizophrenia
A Study for Participants With Schizophrenia
The purpose of this study is to test the hypothesis that 1 or more dose levels of LY2140023 given orally to participants with schizophrenia twice daily for 4 weeks will have significantly greater effect than placebo.
- Trial name
- NCT00520923
- Testing
- LY2140023, Olanzapine
- Where
- 35 sites in Argentina, Austria and 7 more
- Volunteers
- 669 people
- Sponsor
- Denovo Biopharma LLC
Schizophrenia
6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Participants With an Acute Exacerbation of Schizophrenia (P06124)
A multicenter, randomized, parallel-group, double-blind, fixed dose, 6-week trial of the efficacy and safety of asenapine compared with placebo in participants with an acute exacerbation of schizophrenia.
- Trial name
- NCT01098110
- Testing
- Asenapine 5 mg, Asenapine 10 mg
- Volunteers
- 532 people
- Sponsor
- Organon and Co
Schizophrenia, Bipolar Disorder
Effectiveness of Anti-Psychotic in GPs Setting
Evaluating the effectiveness of atypical antipsychotics in the community - a prospective, multicentre, observational study to evaluate the impact on Quality of Life of GP-based management of antipsychotic treatment in Belgium
- Trial name
- Serenity (NCT00543088)
- Where
- 57 sites in Belgium
- Volunteers
- 250 people
- Sponsor
- AstraZeneca
Schizophrenia
Epidemiology of Schizophrenia in Bulgaria
The purpose of this study is to provide accurate, reliable information on schizophrenia clinical management in order to detect unmet medical needs of this disease in terms of: Patient characteristics.
- Trial name
- NCT00984373
- Where
- 7 sites in Bulgaria
- Volunteers
- 440 people
- Sponsor
- AstraZeneca
Schizophrenia
A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia
The objective of this study is to evaluate the pharmacokinetics, safety and efficacy of MP-214 in patients with schizophrenia.
- Trial name
- NCT01626859
- Testing
- MP-214 3mg, MP-214 6mg, MP-214 9mg
- Where
- Japan
- Volunteers
- 38 people
- Sponsor
- Tanabe Pharma Corporation
Schizophrenia
A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia
The purpose of this study is to evaluate the effectiveness and safety of paliperidone palmitate in schizophrenic inpatients who have experienced recent exacerbation of acute schizophrenia (that is within past 4 weeks).
- Trial name
- PREVAIL (NCT01527305)
- Testing
- Paliperidone palmitate
- Where
- 21 sites in China, Malaysia and 2 more
- Volunteers
- 212 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia
Safety and Efficacy of Cariprazine in Schizophrenia
The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of acute exacerbation of schizophrenia.
- Trial name
- NCT01104779
- Testing
- Cariprazine
- Where
- 41 sites in United States, Colombia and 2 more
- Volunteers
- 446 people
- Sponsor
- Forest Laboratories
Schizophrenia, Schizoaffective Disorder
A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective Disorder
The purpose of the study is to compare the time to relapse in patients with schizophrenia and schizoaffective disorders receiving risperidone or haloperidol (antipsychotic medications) for at least 1 year.
- Trial name
- NCT00253110
- Testing
- risperidone, haloperidol
- Volunteers
- 396 people
- Sponsor
- Janssen, LP
Schizophrenia
Brexpiprazole in Patients With Acute Schizophrenia
To determine the efficacy and safety of brexpiprazole for the treatment of adults experiencing an acute episode of schizophrenia.
- Trial name
- NCT01810380
- Testing
- Brexpiprazole, Quetiapine extended release
- Where
- United States
- Volunteers
- 468 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia
This is a multicenter, open-label, adaptive, repeat-dose study to evaluate the safety, tolerability, and pharmacokinetics of iloperidone long-acting injection (LAI) in patients with schizophrenia.
- Trial name
- NCT04712734
- Testing
- Iloperidone
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Vanda Pharmaceuticals
Schizophrenia
Study Evaluating Vabicaserin in Subjects With Schizophrenia
The primary purpose of this protocol is to establish the efficacy, safety, and tolerability of vabicaserin (SCA-136) using a once a day capsule in subjects with acute exacerbations of schizophrenia.
- Trial name
- NCT00563706
- Testing
- vabicaserin, risperidone
- Where
- 33 sites in United States, Canada
- Volunteers
- 199 people
- Sponsor
- Pfizer
Schizophrenia
An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia
The purpose of this study is to evaluate the efficacy and safety of extended-release (ER) paliperidone compared to aripiprazole (atypical antipsychotic) in symptomatic (having symptoms) adolescent participants with schizophrenia…
- Trial name
- NCT01009047
- Testing
- Paliperidone extended release (ER), Aripiprazole
- Where
- 41 sites in United States, India and 5 more
- Volunteers
- 228 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia
A Study of Brenipatide in Adult Participants With Schizophrenia
The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC for treatment of schizophrenia.
- Trial name
- RENEW-Scz-1 (NCT07410507)
- Testing
- Brenipatide
- Where
- 101 sites in United States, Argentina and 5 more
- Volunteers
- 450 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
Bioequivalence Study to Compare Brexpiprazole 4 mg Film Coated Tablets Versus RXULTI 4 mg Film Coated Tablet (Brexpiprazole)
Single dose oral bioequivalence study of Brexpiprazole 4 mg Film Coated Tablets and RXULTI® (Brexpiprazole) 4 mg film-coated tablets in healthy adult human subjects under fasting conditions.
- Trial name
- NCT07266792
- Testing
- Brexpiprazole Film Coated Tablets, RXULTI film coated tablet
- Where
- India
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Schizophrenia
A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers
To assess if PF-04958242 can attenuate the ketamine-induced cognitive impairment in verbal learning and memory, episodic memory and spatial working memory in healthy volunteers.
- Trial name
- NCT01749098
- Testing
- PF-04958242, Ketamine
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Biogen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.